Clinical trials: Opinions
Migraine Disorders, Headache Disorders, Primary
Individualized Prediction of Migraine Attacks Using a Mobile Phone App and Fitbit
This trial is collaboration between Mayo Clinic, Second Opinion Health (Simon Bloch, simon@somobilehealth.com 408-981-3814) and Allergan.
- Conditions
- Migraine Disorders, Headache Disorders, Primary, Headache Disorders, Brain Diseases
- Trial name
- Migraine Alert (NCT02910921)
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Second Opinion Health
Gram-positive, Skin Infections, Mild Eczema/Dermatoses
A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection
The purpose of this study is to evaluate the safety and tolerability of Lytixar™ applied topically to uncomplicated skin infections. Three dose levels of Lytixar™ (1%, 2% and 5%) versus placebo will be tested.
- Conditions
- Gram-positive, Skin Infections, Mild Eczema/Dermatoses, Atopic Dermatitis
- Trial name
- NCT01223222
- Testing
- LTX-109
- Where
- 4 sites in Hungary
- Volunteers
- 24 people
- Sponsor
- Lytix Biopharma AS
New Strategies, GINA 2006
Opinion of Patients Under Treatment That Meets the Criteria of New Treatment Strategy According to GINA 2006
Cross-sectional, one visit study. All the data will be collected through questionnaires. Descriptives statistics will be applied to the data. 832 patients will participate to the study and 104 physicians.
- Conditions
- New Strategies, GINA 2006, Patient Opinion
- Trial name
- EPAGGELIA (NCT00695357)
- Where
- 31 sites in Greece
- Volunteers
- 832 people
- Sponsor
- AstraZeneca
Recurrent Head and Neck Cancer
Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer
This is a two-part clinical study of patients with recurrent Head and Neck Cancer (HNC), who in the opinion of their physician, cannot be satisfactorily treated with surgery, radiation or platinum chemotherapy.
- Trial name
- NCT02422979
- Testing
- PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 160 mg/m^2, PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 320 mg/m^2, PIT: 50 J/cm^2 for superficial lesions or 100 J/cm for interstitial lesions and Drug RM-1929: 640 mg/m^2
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rakuten Medical, Inc.
Cancer
Expanded Access to Provide Copanlisib for Patients With Cancer Who Are Experiencing a Positive Response, as Determined by Their Doctors
The purpose of this Expanded Access Program (EAP) is to allow patients to continue receiving treatment with copanlisib if they are currently having, in the opinion of their healthcare provider, an objective favorable response…
- Trial name
- NCT06238583
- Testing
- Copanlisib (Aliqopa, BAY80-6946)
- Where
- 11 sites in Brazil, Chile and 9 more
- Sponsor
- Bayer
Skin Diseases, Skin Condition
Clinical Validation of AI-Based System for Continuous Remote Monitoring of Patient Severity - Experts' Opinion
The goal of this observational study is to learn if an artificial intelligence (AI) tool, called Legit Health Plus, can track the severity of chronic skin conditions from a distance.
- Trial name
- COVIDX_EVCDAO (NCT06237036)
- Where
- Spain
- Volunteers
- 160 people
- Sponsor
- AI Labs Group S.L